戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 al pro-apoptotic effect of dexamethasone and fluticasone furoate.
2 95% CI 0.75-1.14]) with similar findings for fluticasone furoate (0.90 [0.72-1.11]) and vilanterol (0
3 , vilanterol (25 mug), or the combination of fluticasone furoate (100 mug) and vilanterol (25 mug).
4 locks to receive once daily inhaled placebo, fluticasone furoate (100 mug), vilanterol (25 mug), or t
5 ere pretreated with either cetirizine 10 mg, fluticasone furoate 27.5 mug, or placebo to alleviate th
6                                              Fluticasone furoate, alone or in combination with vilant
7 zation, 715 were assigned to receive inhaled fluticasone furoate and 692 to receive placebo, and 656
8 randomly assigned to initiate treatment with fluticasone furoate and vilanterol (n=2114) or usual car
9 V1) and the increased risk of pneumonia with fluticasone furoate and vilanterol compared with vilante
10 ightened cardiovascular risk, treatment with fluticasone furoate and vilanterol did not affect mortal
11 hose on usual care (977 [71%] of 1373 in the fluticasone furoate and vilanterol group vs 784 [56%] of
12 f a once-daily treatment regimen of combined fluticasone furoate and vilanterol improved asthma contr
13 Across all doses of inhaled corticosteroids, fluticasone furoate and vilanterol reduced exacerbations
14 er for patients who initiated treatment with fluticasone furoate and vilanterol than for those on usu
15 fractures were reported more frequently with fluticasone furoate and vilanterol than with vilanterol
16 , a once-daily treatment regimen of combined fluticasone furoate and vilanterol was associated with a
17                         We hypothesised that fluticasone furoate and vilanterol would prevent more ex
18 patients (605 assigned to usual care, 602 to fluticasone furoate and vilanterol) had a baseline ACT s
19 ms (fluticasone propionate and salmeterol or fluticasone furoate and vilanterol); a control arm (not
20 nts from baseline in patients initiated with fluticasone furoate and vilanterol, compared with 2.8 po
21             Reductions in exacerbations with fluticasone furoate and vilanterol, compared with vilant
22      In seasonal AR, azelastine-fluticasone, fluticasone furoate, and fluticasone propionate were the
23  a combined treatment of the corticosteroid, fluticasone furoate, and the long-acting beta agonist, v
24  COPD to a once-daily inhaled combination of fluticasone furoate at a dose of 100 mug and vilanterol
25 nt were randomly assigned to receive inhaled fluticasone furoate at a dose of 200 mug once daily for
26 ear [95% CI 1-15]) with similar findings for fluticasone furoate (difference 8 mL per year [95% CI 1-
27  the once-daily inhaled corticosteroid (ICS) fluticasone furoate (FF) and long-acting beta(2) -agonis
28                                              Fluticasone furoate (FF) is a novel, once-daily ICS asth
29   Genotyping and imputation was performed in fluticasone furoate (FF) or fluticasone propionate-treat
30 tructive Pulmonary Disease Treatment) trial, fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol
31 ontrolled trial, once-daily inhaled placebo, fluticasone furoate (FF; 100 mug), vilanterol (VI; 25 mu
32                       Treatment with inhaled fluticasone furoate for 14 days did not result in a shor
33     A total of 24 participants (3.7%) in the fluticasone furoate group had urgent-care or emergency d
34 tion; 4111 in the placebo group, 4135 in the fluticasone furoate group, 4118 in the vilanterol group,
35 18% in the combination group, and 17% in the fluticasone furoate group, and 17% in the vilanterol gro
36 roup, 6% in the combination group, 5% in the fluticasone furoate group, and 4% in the vilanterol grou
37 ative reduction; p=0.137) or the components (fluticasone furoate, HR 0.91 [0.77-1.08]; p=0.284; vilan
38  vilanterol plus 50 mug, 100 mug, or 200 mug fluticasone furoate in patients with moderate-to-severe
39 ng-term effect of the inhaled corticosteroid fluticasone furoate on exacerbation frequency.
40 ined with either 50 mug, 100 mug, or 200 mug fluticasone furoate once daily.
41        There was no evidence that the use of fluticasone furoate resulted in a shorter time to recove
42                                  Addition of fluticasone furoate to vilanterol was associated with a
43 itude of benefit of regimens containing ICS (fluticasone furoate-umeclidinium-vilanterol n=4151 and f
44 ng once-daily single-inhaler triple therapy (fluticasone furoate-umeclidinium-vilanterol) with dual i
45 ction in all-cause mortality (ACM) risk with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI)
46 aring 24 weeks of once-daily triple therapy (fluticasone furoate/umeclidinium/vilanterol 100 mug/62.5
47  mug and vilanterol at a dose of 25 mug (the fluticasone furoate-vilanterol group) or to usual care (
48 s serious adverse events of pneumonia in the fluticasone furoate-vilanterol group.
49 e furoate-umeclidinium-vilanterol n=4151 and fluticasone furoate-vilanterol n=4134) in reducing rates
50 inium-vilanterol) with dual inhaled therapy (fluticasone furoate-vilanterol or umeclidinium-vilantero
51 (95% confidence interval, 1.1 to 15.2), with fluticasone furoate-vilanterol therapy than with usual c
52 uL or more; the corresponding rate ratio for fluticasone furoate-vilanterol versus umeclidinium-vilan
53 led corticosteroid/long-acting beta2-agonist fluticasone furoate/vilanterol 100/25 mug or placebo (7-
54 bation rate was noted between the 200/25 mug fluticasone furoate/vilanterol group and the vilanterol
55 ight deaths from pneumonia were noted in the fluticasone furoate/vilanterol groups compared with none
56 e and severe exacerbations were noted in all fluticasone furoate/vilanterol groups than in the vilant
57 e and severe exacerbations were noted in all fluticasone furoate/vilanterol groups than in the vilant
58                                              Fluticasone furoate/vilanterol safety profile was simila
59 P < 0.001) reduction in residual volume with fluticasone furoate/vilanterol versus placebo.
60 ual medications, azelastine-fluticasone, and fluticasone furoate were the most frequently highest-ran
61 led combination of either 100 mug or 200 mug fluticasone furoate with 25 mug vilanterol or optimised